Lorentz, C. U., Verbout, N. G., Wallisch, M., Hagen, M. W., Shatzel, J. J., Olson, S. R., . . . Tucker, E. I. (2019). The contact activation inhibitor and factor XI antibody, AB023, produces safe, dose-dependent anticoagulation in a phase 1 first-in-human trial. Arterioscler Thromb Vasc Biol.
Citación estilo ChicagoLorentz, Christina U., et al. "The Contact Activation Inhibitor and Factor XI Antibody, AB023, Produces Safe, Dose-dependent Anticoagulation in a Phase 1 First-in-human Trial." Arterioscler Thromb Vasc Biol 2019.
Cita MLALorentz, Christina U., et al. "The Contact Activation Inhibitor and Factor XI Antibody, AB023, Produces Safe, Dose-dependent Anticoagulation in a Phase 1 First-in-human Trial." Arterioscler Thromb Vasc Biol 2019.